Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01

Journal of Pediatric Hematology/Oncology

Volumn 33, Issue 1, 2011, Pages 31-34

  Fousseyni, Traore ^a   Diawara, Maimouna ^a   Pasquier, Eddy ^b   André, Nicolas ^c  

^a HÔPITAL GABRIEL TOURÉ   (Mali)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c TIMONE HOSPITAL   (France)

Author keywords

angiogenesis; developing country; Metronomic chemotherapy; pediatric oncology; tumor dormancy

Indexed keywords

CYCLOPHOSPHAMIDE; METHOTREXATE; VINCRISTINE;

ANEMIA; ARTICLE; CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LOWEST INCOME GROUP; MALE; MAXIMUM TOLERATED DOSE; METRONOMIC CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROBLASTOMA; NEUROBLASTOMA; NEUTROPENIA; PRIORITY JOURNAL; RETINOBLASTOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DEVELOPING COUNTRIES; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; METHOTREXATE; PILOT PROJECTS; PROSPECTIVE STUDIES; RETINOBLASTOMA; TREATMENT OUTCOME; VINCRISTINE; WILMS TUMOR;

EID: 78650792305     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3182018ab8     Document Type: Article

References (18)

1. Kellie SJ, Howard SC. Global child health priorities: what role for paediatric oncologists? Europ J Cancer. 2008;44:2388-2396.
2. Lemerle J, Msefer Alaoui F, Harif M, et al. Peut-on traiter les cancers des enfants en Afrique. L'action du Groupe Francoafricain d'oncologie Pédiatrique. MT Pediatr. 2003;6:192-197.
3. Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: New rationale for new directions. Nature Reviews Clin Oncol. 2010;7:455-465.
4. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002;13:73-80.
5. Pasquier E, André N, Braguer D. Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: Implications for cancer treatment. Curr Cancer Drug Targets. 2007;7:566-581.
6. Kieran MW, Turner CD, Rubin JB, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol. 2005;27:573-581.
7. Choi LM, Rood B, Kamani N, et al. Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors. Pediatr Blood Cancer. 2008;50:970-975.
8. André N, Rome A, Coze C, et al. Metronomical etoposide/ cyclophosphamide/celocoxib regimen given to children with refractory cancer: A preliminary monocentric study. Clin Pharm. 2008;30:1336-1340.
9. Stempak D, Gammon J, Halton J, et al. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol. 2006;28:720-728.
10. Aguirre-Ghiso J, Models A. mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2006;7:834-846.
11. André N, Pasquier E. Response to "intermittent androgen blockade should be regarded as standard therapy in prostate cancer". Nat Clin Pract Oncol. 2009;6:E1.
12. André N, Pasquier E. For cancer, seek and destroy or live and let live? Nature. 2009;460:324.
13. Fidler IJ, Ellis LM. Chemotherapeutic drugs-more really is not better. Nat Med. 2000;6:500-502.
14. Sterba J, Valik D, Mudry P, et al. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie. 2006;29:308-313.
15. Ló pez-Aguilar E, Sepú lveda-Vildó sola AC, Rivera-Má rquez H, et al. Security and maximal tolerated doses of fluvastatin in pediatric cancer patients. Arch Med Res. 1999;30:128-131.
16. Dimitroulakos J, Ye LY, Benzaquen M, et al. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: Therapeutic implications. Clin Cancer Res. 2001;7:158-167.
17. André N, Padovani L, Verschuur A. Metronomic chemotherapy: Back to the future! Drug New Perspect. 2010;23: 143-151.
18. Wolff JE, Kramm C, Kortmann RD, et al. Valproic acid was well tolerated in heavily pretreated pediatric patients with highgrade glioma. J Neurooncol. 2008;90:309-314.